These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23548717)

  • 1. Host genomics and control of tuberculosis infection.
    Cobat A; Orlova M; Barrera LF; Schurr E
    Public Health Genomics; 2013; 16(1-2):44-9. PubMed ID: 23548717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evolution of IGRA researches].
    Ariga H; Harada N
    Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
    Sato S; Nagai H
    Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon gamma release assays: principles and practice.
    Lalvani A; Pareek M
    Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):245-52. PubMed ID: 19783328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-gamma release assay test characteristics depend upon the prevalence of active tuberculosis.
    Davidow AL
    Int J Tuberc Lung Dis; 2009 Nov; 13(11):1411-5. PubMed ID: 19861015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution of host genetics to tuberculosis pathogenesis.
    Schurr E
    Kekkaku; 2011 Jan; 86(1):17-28. PubMed ID: 21401002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics of a diagnostic method for tuberculosis infection based on whole blood interferon-gamma assay].
    Harada N
    Kekkaku; 2006 Nov; 81(11):681-6. PubMed ID: 17154047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-γ release assays versus tuberculin skin test for targeting people for tuberculosis preventive treatment: an evidence-based review.
    Muñoz L; Santin M
    J Infect; 2013 Apr; 66(4):381-7. PubMed ID: 23298892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: a case-control study.
    Alsleben N; Ruhwald M; Rüssmann H; Marx FM; Wahn U; Magdorf K
    Scand J Infect Dis; 2012 Apr; 44(4):256-62. PubMed ID: 22103555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent Mycobacterium tuberculosis infection in lupus patients.
    Yilmaz N; Zehra Aydin S; Inanc N; Karakurt S; Direskeneli H; Yavuz S
    Lupus; 2012 Apr; 21(5):491-5. PubMed ID: 22140142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.
    Chen YM; Chen HH; Lai KL; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2013 Apr; 52(4):697-704. PubMed ID: 23264552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latent tuberculosis infections in hard-to-reach drug using population-detection, prevention and control.
    Hwang LY; Grimes CZ; Beasley RP; Graviss EA
    Tuberculosis (Edinb); 2009 Dec; 89 Suppl 1():S41-5. PubMed ID: 20006303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevalence of latent infection with Mycobacterium tuberculosis in Mazovia Region using interferon gamma release assay after stimulation with specific antigens ESAT-6 and CFP-10].
    Kuś J; Demkow U; Lewandowska K; Korzeniewska-Koseła M; Rabczenko D; Siemion-Szcześniak I; Białas-Chromiec B; Bychawska M; Sapigórski P; Maciejewski J
    Pneumonol Alergol Pol; 2011; 79(6):407-18. PubMed ID: 22028119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 100 year update on diagnosis of tuberculosis infection.
    Lalvani A; Pareek M
    Br Med Bull; 2010; 93():69-84. PubMed ID: 19926636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection.
    Manuel O; Kumar D
    Expert Rev Mol Diagn; 2008 May; 8(3):247-56. PubMed ID: 18598104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New tests will improve detection of latent TB.
    Chapman AL
    Practitioner; 2011 Nov; 255(1745):23-6, 2-3. PubMed ID: 22235551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of the tuberculin skin test and the T-SPOT.TB assay among students in a low-tuberculosis incidence setting.
    Talbot EA; Harland D; Wieland-Alter W; Burrer S; Adams LV
    J Am Coll Health; 2012; 60(1):94-6. PubMed ID: 22171735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.